The incidence of hypothyroidism was 19.6% in the combination therapy, 9.9% in anti-PD-1 therapy, 8.7% in anti-PD-L1 therapy, 8.3% in anti-CTLA-4 therapy, and 3.9% in sequential therapy of anti-PD-1 and PD-L1. Here, PDCD1 is linked to hypothyroidism.